Serina Therapeutics, Inc.SERNYSE
LOADING
|||
Operating Income Growth Under Pressure
Trending lower, above historical average.
Left:
||||
Year-over-year operating income growth rate
Latest
-14.86%
↑ 52% above average
Average (34q)
-30.99%
Historical baseline
Range
High:116.47%
Low:-1063.07%
Volatility
-3806.8%
Relatively stable
| Period | Value |
|---|---|
| Q3 2025 | -14.86% |
| Q2 2025 | 5.00% |
| Q1 2025 | -5.57% |
| Q4 2024 | -4.46% |
| Q3 2024 | -37.40% |
| Q2 2024 | -66.57% |
| Q1 2024 | -1063.07% |
| Q4 2023 | 116.47% |
| Q3 2023 | -54.81% |
| Q2 2023 | 1.77% |
| Q1 2023 | 46.02% |
| Q4 2022 | -14.97% |
| Q3 2022 | 2.58% |
| Q2 2022 | 22.47% |
| Q1 2022 | -8.46% |
| Q4 2021 | -13.02% |
| Q3 2021 | 24.08% |
| Q2 2021 | 3.84% |
| Q1 2021 | 6.29% |
| Q4 2020 | -1.79% |
| Q3 2020 | 8.42% |
| Q2 2020 | 17.84% |
| Q1 2020 | -17.64% |
| Q4 2019 | 17.17% |
| Q3 2019 | 4.74% |
| Q2 2019 | 1.94% |
| Q1 2019 | -4.53% |
| Q4 2018 | -52.22% |
| Q3 2018 | -3.37% |
| Q2 2018 | 22.43% |
| Q1 2018 | -76.57% |
| Q4 2017 | 19.27% |
| Q3 2017 | 6.31% |
| Q2 2017 | 28.20% |
| Q1 2017 | 0.00% |